Back to All NewsNorth America Facial Injectable Market to be Worth US$5.8 Billion by 2024
Posted By American Med Spa Association, Friday, January 20, 2017
Share
The North America Facial Injectables Market is quite monopolistic in nature with one player dominating the overall market dynamics. As of 2016, Allergan Plc., held a share 62.0% in the regional market. The company dominance is a result of the strong brand value of its drugs like Botox & Juvederm. Presently, Botox is leading the market and is expected to retain its stance all throughout 2024.
According to the research report, the North America facial injectables market is expected to reach a valuation of US$5.8 bn by the end of 2024 as compared to US$2.1 bn by the end of 2015. Between the forecast years of 2016 and 2024, the global market is expected to rise at a CAGR of 12.0%.
U.S. to be Frontrunner in Regional Market with Changing Lifestyles of Consumers
The overall market has been segmented into the U.S. and Canada on the basis of geography. Out of the two countries, the U.S. is expected to assume the lead in the overall market due to a high demand for botulinum toxins and dermal fillers. Improving lifestyles and growing preference for minimally invasive surgeries are expected to drive the demand for facial injectables across the U.S.
Read more at PRNewswire >>
According to the research report, the North America facial injectables market is expected to reach a valuation of US$5.8 bn by the end of 2024 as compared to US$2.1 bn by the end of 2015. Between the forecast years of 2016 and 2024, the global market is expected to rise at a CAGR of 12.0%.
U.S. to be Frontrunner in Regional Market with Changing Lifestyles of Consumers
The overall market has been segmented into the U.S. and Canada on the basis of geography. Out of the two countries, the U.S. is expected to assume the lead in the overall market due to a high demand for botulinum toxins and dermal fillers. Improving lifestyles and growing preference for minimally invasive surgeries are expected to drive the demand for facial injectables across the U.S.
Read more at PRNewswire >>
